Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study (PACIFIC-STROKE)

Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate Efficacy and Safety of BAY2433334 in Patients Following an Acute Non-cardioembolic Ischemic Stroke

3 new sites added. All sites are initiated. Recruitment ends Aug 2021. Austin site closed after initiation as site could not complete necessary trainings and documentation to start enrolment. Recruitment is competitive. Australia needs to meet or exceed recruitment commitment to ensure substantial contribution to this program.

Lead PI: Professor Bruce Campbell

Status: Recruiting, ASTN endorsed, Site selection 

No. of Patients Currently Recruited: 87                                No. of Patients Required: 130

Participating Australian and New Zealand Sites:

Royal Melbourne Hospital, Royal Adelaide Hospital, Liverpool Hospital, John Hunter Hospital, Royal North Shore Hospital, Gold Coast University Hospital, Box Hill Hospital, Sunshine Coast University Hospital, Austin Health, Fiona Stanley Hospital, The Alfred, Princess Alexandra Hospital, Blacktown Hospital, Ballarat Health Services

Trial URL:

Related Posts